Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Harvard Business School
Baxter
Mallinckrodt

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Tecovirimat - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for tecovirimat and what is the scope of patent protection?

Tecovirimat is the generic ingredient in one branded drug marketed by Siga Technologies and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tecovirimat has sixty-seven patent family members in twenty countries.

One supplier is listed for this compound.

Summary for tecovirimat
International Patents:67
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 15
Clinical Trials: 5
Patent Applications: 16
DailyMed Link:tecovirimat at DailyMed
Recent Clinical Trials for tecovirimat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SIGA TechnologiesPhase 3
Biomedical Advanced Research and Development AuthorityPhase 3
National Institutes of Health (NIH)Phase 2

See all tecovirimat clinical trials

Synonyms for tecovirimat
4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide
458T318
816458-31-8
869572-92-9
AKOS030260536
AN-27268
Benzamide, N-((3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)-, rel-
Benzamide, N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-, rel-
CHEMBL1257073
CS-3464
DB12020
F925RR824R
HY-14805
N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide
N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide
N-(dioxo[?]yl)-4-(trifluoromethyl)benzamide
N-[(3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)benzamide
SCHEMBL404743
SIGA 246
SIGA-246
ST 246
ST-246
Tecovirimat [USAN:INN]
TPOXX
UNII-F925RR824R
ZINC35323125

US Patents and Regulatory Information for tecovirimat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.